Inhibition of the HSP90 chaperone leads to degradation of the HER2 receptor. The HSP90 inhibitor tanespimycin in combination with trastuzumab is active in patients with HER2-overexpressing metastatic breast cancer. This combination is one of several HER2-targeted therapies that will significantly improve the outcome of patients with this subtype of breast cancer.
|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical Cancer Research|
|State||Published - Aug 1 2011|
ASJC Scopus subject areas
- Cancer Research